231 related articles for article (PubMed ID: 10981176)
1. Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers.
Elliott WJ
Curr Hypertens Rep; 2000 Aug; 2(4):402-11. PubMed ID: 10981176
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
3. [Angiotensin I receptor blockers for heart failure].
Fruhwald FM; Kickenweiz E; Zweiker R; Klein W
Wien Med Wochenschr; 2001; 151(7-8):157-9. PubMed ID: 11450163
[TBL] [Abstract][Full Text] [Related]
4. [Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure].
Rakugi H; Ogihara T
Nihon Rinsho; 2001 Oct; 59(10):2051-61. PubMed ID: 11676153
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
Krum H; Nolly H; Workman D; He W; Roniker B; Krause S; Fakouhi K
Hypertension; 2002 Aug; 40(2):117-23. PubMed ID: 12154100
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of angiotensin receptor blockers in hypertension.
Cheung BM
Expert Opin Investig Drugs; 2006 Jun; 15(6):625-35. PubMed ID: 16732715
[TBL] [Abstract][Full Text] [Related]
7. [Angiotensin receptor blockers--significance for the therapy of hypertension].
Magometschnigg D
Wien Med Wochenschr; 2001; 151(7-8):153-6. PubMed ID: 11450162
[TBL] [Abstract][Full Text] [Related]
8. [Angiotensin II receptor blockers: current status and future prospects].
Corvol P; Plouin PF
Drugs; 2002; 62 Spec No 1():53-64. PubMed ID: 12036389
[TBL] [Abstract][Full Text] [Related]
9. Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
Martin J; Krum H
Pharmacol Res; 2002 Sep; 46(3):203-12. PubMed ID: 12220962
[TBL] [Abstract][Full Text] [Related]
10. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
Jorde UP; Ennezat PV; Lisker J; Suryadevara V; Infeld J; Cukon S; Hammer A; Sonnenblick EH; Le Jemtel TH
Circulation; 2000 Feb; 101(8):844-6. PubMed ID: 10694521
[TBL] [Abstract][Full Text] [Related]
11. Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine.
Ball SG; White WB
Am J Cardiol; 2003 May; 91(10A):15G-21G. PubMed ID: 12781904
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
13. A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
Erhardt LR
Int J Clin Pract; 2005 May; 59(5):571-8. PubMed ID: 15857354
[TBL] [Abstract][Full Text] [Related]
14. [Ace inhibitors and angiotensin II receptor antagonists for therapy of chronic heart failure].
Kuwabara Y; Komuro I
Nihon Naika Gakkai Zasshi; 2005 Feb; 94(2):255-61. PubMed ID: 15768589
[No Abstract] [Full Text] [Related]
15. The renin-angiotensin system: the role of inhibitors, blockers, and genetic polymorphisms in the treatment and prevention of heart failure.
Hebert PR; Foody JM; Hennekens CH
Curr Vasc Pharmacol; 2003 Mar; 1(1):33-9. PubMed ID: 15320851
[TBL] [Abstract][Full Text] [Related]
16. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
Pfeffer MA
Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin receptor blockers in congestive heart failure: evidence, concerns, and controversies.
Bhatia V; Bhatia R; Mathew B
Cardiol Rev; 2005; 13(6):297-303. PubMed ID: 16230887
[TBL] [Abstract][Full Text] [Related]
18. Effects of angiotensin-converting enzyme inhibitor versus valsartan on cellular signaling events in heart transplant.
White M; Ross H; Levesque S; Whittom L; Pelletier GB; Racine N; Meloche S; Voisin L
Ann Pharmacother; 2009 May; 43(5):831-9. PubMed ID: 19417110
[TBL] [Abstract][Full Text] [Related]
19. The value of irbesartan in the management of hypertension.
Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
[TBL] [Abstract][Full Text] [Related]
20. New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure.
Martineau P; Goulet J
Ann Pharmacother; 2001 Jan; 35(1):71-84. PubMed ID: 11197588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
